Biologics CDMO Market, By Type (Mammalian, Non-Mammalian), By Product Type (Biologics (Recombinant Proteins, Vaccines, Monoclonal, Antisense & Molecular Therapy, and Other Biologics) and Biosimilars), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI511023 | Publish Date: March 2024 | No. of Pages: 170

Biologics CDMO Market Companies

  • Lonza Group
  • Catalent Inc.
  • Samsung Biologics
  • Eurofins Scientific
  • Boehringer Ingelheim Group
  • FUJIFILM Diosynth Biotechnologies Inc.
  • Wuxi Biologics
  • LabCorp Drug Development
  • Cambrex Corporation
  • AGC Biologics

Recent News:

  • Samsung Biologics and Pfizer inked an agreement in March 2023 for Samsung to produce COVID-19 vaccines for Moderna. The contract is worth $183 million and is valid until 2029. 15% of Samsung's $1.2 billion in revenue from 2021 will go toward this new agreement.
  • Takeda announced in March 2023 that it would invest roughly $765 million to build a new production facility in Osaka, Japan. Thanks to the construction of this new plant, Takeda will have the largest operational plasma-based manufacturing capacity by 2030.
  • Lonza intends to invest $518 million in a sizable fill-finish manufacturing facility in Stein, Switzerland, by July 2022. It is anticipated that a new manufacturing facility will be finished in 2026. This facility will provide comprehensive, integrated CDMO services.